Each sub-question captures a contributing factor (timely action, approval-vs-CRL, and CMC risk) that blend into the probability of approval before the deadline; weighted_average combines them since they are correlated and all depend on the same underlying review trajectory.
## Cross-Market Signals ### No signal found
1. [sq1 | question_description | STRONG cred 92 | UP | DATED] FDA extended Orca-T BLA review and set a new PDUFA target action date of July 6, 2026. 2. [sq1 | question_description | STRONG cred 90 | UP | DATED] The extension followed updated CMC information and FDA did not request additional clinical data. 3. [sq1 | code_execution | WEAK cred 35 | NEUTRAL | VERY_RECENT] A rough base-rate triangulation for FDA approval given a CMC-only extension produced a combined estimate of 0.464. 4. [sq1 | article_search | MODERATE cred 60 | DOWN | DATED] FDA watchers warn of internal 'chaos,' staff losses, and regulatory delays affecting the agency's ability to keep up with approvals (March 2026). 5. [sq1 | article_search | MODERATE cred 70 | NEUTRAL | RECENT] FDA Commissioner Marty Makary resigned in May 2026 after a rocky 13-month tenure amid leadership turmoil. 6. [sq2 | question_description | MODERATE cred 90 | UP | DATED] FDA approved Omisirge, a modified allogeneic cord-blood cell therapy for hematologic malignancies, in April 2023, establishing precedent for cell-therapy approvals in this space. 7. [sq2 | article_search | MODERATE cred 65 | DOWN | DATED] FDA denied or discouraged at least eight drug applications in the past year, including gene therapies, citing concerns about supporting evidence (March 2026). 8. [sq2 | article_search | MODERATE cred 60 | DOWN | RECENT] FDA withheld approval of a melanoma drug despite clinical benefit, amid confusion under Makary's leadership (May 2026). 9. [sq3 | question_description | MODERATE cred 85 | DOWN | DATED] The Orca-T review extension was driven by updated CMC information, indicating CMC was an active area of FDA focus. 10. [sq3 | article_search | WEAK cred 50 | NEUTRAL | DATED] A massive eye drop recall in 2026 reflected ongoing FDA manufacturing-inspection issues, highlighting agency scrutiny of CMC/sterility (April 2026). ## Cross-Market Signals ### No signal found Information gaps: - No Orca-T-specific news on inspection outcomes or CMC resolution status post-extension - Base rate for approval vs CRL when extension was CMC-only and no clinical data requested - No data on facility inspection status for Orca Bio manufacturing site - No expert/analyst commentary specifically on Orca-T's approval odds Key uncertainties: - Whether updated CMC package fully satisfies FDA reviewers - Impact of FDA leadership turnover and staffing on timely action - Whether FDA issues a second extension rather than acting by July 6, 2026 - Whether facility inspection (if required) is completed and clean
You are an elite superforecaster using Tetlock-style Fermi decomposition. Estimate each sub-question INDEPENDENTLY, then provide a holistic estimate. The pipeline will mathematically recombine the sub-question estimates — your job is to give the most accurate per-component probabilities.
## Question
Will FDA approve Orca-T for hematologic malignancies before September 1, 2026?
## Description / Resolution Criteria
## Description
FDA [extended](https://orcabio.com/orca-bio-announces-fda-review-extension-of-bla-for-orca-t-for-the-treatment-of-hematologic-malignancies/) the BLA review for Orca-T and set a new PDUFA target action date of July 6, 2026; the extension followed updated CMC information and did not request additional clinical data. FDA [approved](https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell) Omisirge, a substantially modified allogeneic cord-blood-based cell therapy, for patients with hematologic malignancies on April 17, 2023.
`{"format": "bot_tournament_question", "info": {"hash_id": "b1535d606941245d", "sheet_id": "47"}}`
## Resolution Criteria
This question resolves as Yes if FDA approves Orca-T for any hematologic malignancy indication before September 1, 2026. It resolves as No if FDA issues a CRL, extends review without approval, the application is withdrawn, or no approval is public before September 1, 2026.
## Sub-question decomposition
- (w=0.40) Will the FDA take action on the Orca-T BLA on or before its July 6, 2026 PDUFA target action date (rather than another extension/delay)? — The PDUFA date falls before the Sept 1, 2026 resolution cutoff, so timely action is a precondition for a Yes resolution.
- (w=0.45) Given timely FDA action, will the action be an approval rather than a CRL? — The core driver: the extension was for CMC information with no new clinical data requested, suggesting the clinical pack
- (w=0.15) Are there CMC, manufacturing, or inspection issues that could trigger a CRL or further delay for Orca-T? — CMC was the reason for the extension; unresolved manufacturing/facility inspection issues are a common cause of cell-the
Combination rule: **weighted_average**
## Synthesized evidence
1. [sq1 | question_description | STRONG cred 92 | UP | DATED] FDA extended Orca-T BLA review and set a new PDUFA target action date of July 6, 2026.
2. [sq1 | question_description | STRONG cred 90 | UP | DATED] The extension followed updated CMC information and FDA did not request additional clinical data.
3. [sq1 | code_execution | WEAK cred 35 | NEUTRAL | VERY_RECENT] A rough base-rate triangulation for FDA approval given a CMC-only extension produced a combined estimate of 0.464.
4. [sq1 | article_search | MODERATE cred 60 | DOWN | DATED] FDA watchers warn of internal 'chaos,' staff losses, and regulatory delays affecting the agency's ability to keep up with approvals (March 2026).
5. [sq1 | article_search | MODERATE cred 70 | NEUTRAL | RECENT] FDA Commissioner Marty Makary resigned in May 2026 after a rocky 13-month tenure amid leadership turmoil.
6. [sq2 | question_description | MODERATE cred 90 | UP | DATED] FDA approved Omisirge, a modified allogeneic cord-blood cell therapy for hematologic malignancies, in April 2023, establishing precedent for cell-therapy approvals in this space.
7. [sq2 | article_search | MODERATE cred 65 | DOWN | DATED] FDA denied or discouraged at least eight drug applications in the past year, including gene therapies, citing concerns about supporting evidence (March 2026).
8. [sq2 | article_search | MODERATE cred 60 | DOWN | RECENT] FDA withheld approval of a melanoma drug despite clinical benefit, amid confusion under Makary's leadership (May 2026).
9. [sq3 | question_description | MODERATE cred 85 | DOWN | DATED] The Orca-T review extension was driven by updated CMC information, indicating CMC was an active area of FDA focus.
10. [sq3 | article_search | WEAK cred 50 | NEUTRAL | DATED] A massive eye drop recall in 2026 reflected ongoing FDA manufacturing-inspection issues, highlighting agency scrutiny of CMC/sterility (April 2026).
## Cross-Market Signals
### No signal found
Information gaps:
- No Orca-T-specific news on inspection outcomes or CMC resolution status post-extension
- Base rate for approval vs CRL when extension was CMC-only and no clinical data requested
- No data on facility inspection status for Orca Bio manufacturing site
- No expert/analyst commentary specifically on Orca-T's approval odds
Key uncertainties:
- Whether updated CMC package fully satisfies FDA reviewers
- Impact of FDA leadership turnover and staffing on timely action
- Whether FDA issues a second extension rather than acting by July 6, 2026
- Whether facility inspection (if required) is completed and clean
## Required pre-forecast walkthrough
Before giving probabilities, walk through these explicitly:
(a) The time left until the question resolves.
(b) The status quo outcome — what happens if nothing changes from today.
(c) A brief scenario that results in NO.
(d) A brief scenario that results in YES.
## Calibration guidance
- **Estimate each sub-question in isolation.** Do not let your answer to one sub-question anchor your answer to another. This is the core of Fermi decomposition — independence forces more careful reasoning per factor.
- **Anchor on the status quo.** Require strong specific evidence to move far from it.
- 0.05 / 0.95 require strong, multi-source evidence. Avoid >0.97 or <0.03 unless the outcome is already settled or near-tautological — overconfident misses are punished heavily by the log score.
- **Anchor on prediction markets.** If liquid market prices (Polymarket / Kalshi) or a community forecast appear in the evidence, treat them as a strong, well-calibrated prior. Your final estimate should rarely sit more than ~15 percentage points from a liquid market on the SAME question — move further only with specific evidence the market lacks.
- **Treat research as fallible, not ground truth.** A single-source or "very recent" claim — especially one the evidence flags as unverified, possibly AI-generated, or low-credibility — must not drive you to near-certainty. When a load-bearing fact is unverified, keep at least 10-15% on the chance it is wrong.
- **Also provide a holistic estimate** — your overall gut feeling about the main question, BEFORE you see the mathematical combination. This serves as a sanity check: if the Fermi result and holistic estimate diverge wildly, something is wrong.
## Output
Return ONLY valid JSON, no markdown fences:
{
"rationale": "<address (a) (b) (c) (d) above — 5-8 sentences total>",
"sub_question_estimates": {
"sq1": <float in [0.01, 0.99]>,
"sq2": <float in [0.01, 0.99]>,
"sq3": <float in [0.01, 0.99]>
},
"holistic_p_yes": <float in [0.01, 0.99] — your overall estimate ignoring the decomposition>,
"what_would_change_my_mind": "<1-2 sentences: what new info would push you above 70% or below 30%>"
}
{
"forecast": {
"combination_logic": "weighted_average",
"evidence_brief": "1. [sq1 | question_description | STRONG cred 92 | UP | DATED] FDA extended Orca-T BLA review and set a new PDUFA target action date of July 6, 2026.\n2. [sq1 | question_description | STRONG cred 90 | UP | DATED] The extension followed updated CMC information and FDA did not request additional clinical data.\n3. [sq1 | code_execution | WEAK cred 35 | NEUTRAL | VERY_RECENT] A rough base-rate triangulation for FDA approval given a CMC-only extension produced a combined estimate of 0.464.\n4. [sq1 | article_search | MODERATE cred 60 | DOWN | DATED] FDA watchers warn of internal \u0027chaos,\u0027 staff losses, and regulatory delays affecting the agency\u0027s ability to keep up with approvals (March 2026).\n5. [sq1 | article_search | MODERATE cred 70 | NEUTRAL | RECENT] FDA Commissioner Marty Makary resigned in May 2026 after a rocky 13-month tenure amid leadership turmoil.\n6. [sq2 | question_description | MODERATE cred 90 | UP | DATED] FDA approved Omisirge, a modified allogeneic cord-blood cell therapy for hematologic malignancies, in April 2023, establishing precedent for cell-therapy approvals in this space.\n7. [sq2 | article_search | MODERATE cred 65 | DOWN | DATED] FDA denied or discouraged at least eight drug applications in the past year, including gene therapies, citing concerns about supporting evidence (March 2026).\n8. [sq2 | article_search | MODERATE cred 60 | DOWN | RECENT] FDA withheld approval of a melanoma drug despite clinical benefit, amid confusion under Makary\u0027s leadership (May 2026).\n9. [sq3 | question_description | MODERATE cred 85 | DOWN | DATED] The Orca-T review extension was driven by updated CMC information, indicating CMC was an active area of FDA focus.\n10. [sq3 | article_search | WEAK cred 50 | NEUTRAL | DATED] A massive eye drop recall in 2026 reflected ongoing FDA manufacturing-inspection issues, highlighting agency scrutiny of CMC/sterility (April 2026).\n\n## Cross-Market Signals\n\n### No signal found\n\nInformation gaps:\n - No Orca-T-specific news on inspection outcomes or CMC resolution status post-extension\n - Base rate for approval vs CRL when extension was CMC-only and no clinical data requested\n - No data on facility inspection status for Orca Bio manufacturing site\n - No expert/analyst commentary specifically on Orca-T\u0027s approval odds\n\nKey uncertainties:\n - Whether updated CMC package fully satisfies FDA reviewers\n - Impact of FDA leadership turnover and staffing on timely action\n - Whether FDA issues a second extension rather than acting by July 6, 2026\n - Whether facility inspection (if required) is completed and clean",
"forecast_prompt": "You are an elite superforecaster using Tetlock-style Fermi decomposition. Estimate each sub-question INDEPENDENTLY, then provide a holistic estimate. The pipeline will mathematically recombine the sub-question estimates \u2014 your job is to give the most accurate per-component probabilities.\n\n## Question\nWill FDA approve Orca-T for hematologic malignancies before September 1, 2026?\n\n## Description / Resolution Criteria\n## Description\nFDA [extended](https://orcabio.com/orca-bio-announces-fda-review-extension-of-bla-for-orca-t-for-the-treatment-of-hematologic-malignancies/) the BLA review for Orca-T and set a new PDUFA target action date of July 6, 2026; the extension followed updated CMC information and did not request additional clinical data. FDA [approved](https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell) Omisirge, a substantially modified allogeneic cord-blood-based cell therapy, for patients with hematologic malignancies on April 17, 2023.\n\n`{\"format\": \"bot_tournament_question\", \"info\": {\"hash_id\": \"b1535d606941245d\", \"sheet_id\": \"47\"}}`\n\n## Resolution Criteria\nThis question resolves as Yes if FDA approves Orca-T for any hematologic malignancy indication before September 1, 2026. It resolves as No if FDA issues a CRL, extends review without approval, the application is withdrawn, or no approval is public before September 1, 2026.\n\n## Sub-question decomposition\n- (w=0.40) Will the FDA take action on the Orca-T BLA on or before its July 6, 2026 PDUFA target action date (rather than another extension/delay)? \u2014 The PDUFA date falls before the Sept 1, 2026 resolution cutoff, so timely action is a precondition for a Yes resolution.\n- (w=0.45) Given timely FDA action, will the action be an approval rather than a CRL? \u2014 The core driver: the extension was for CMC information with no new clinical data requested, suggesting the clinical pack\n- (w=0.15) Are there CMC, manufacturing, or inspection issues that could trigger a CRL or further delay for Orca-T? \u2014 CMC was the reason for the extension; unresolved manufacturing/facility inspection issues are a common cause of cell-the\n\nCombination rule: **weighted_average**\n\n## Synthesized evidence\n1. [sq1 | question_description | STRONG cred 92 | UP | DATED] FDA extended Orca-T BLA review and set a new PDUFA target action date of July 6, 2026.\n2. [sq1 | question_description | STRONG cred 90 | UP | DATED] The extension followed updated CMC information and FDA did not request additional clinical data.\n3. [sq1 | code_execution | WEAK cred 35 | NEUTRAL | VERY_RECENT] A rough base-rate triangulation for FDA approval given a CMC-only extension produced a combined estimate of 0.464.\n4. [sq1 | article_search | MODERATE cred 60 | DOWN | DATED] FDA watchers warn of internal \u0027chaos,\u0027 staff losses, and regulatory delays affecting the agency\u0027s ability to keep up with approvals (March 2026).\n5. [sq1 | article_search | MODERATE cred 70 | NEUTRAL | RECENT] FDA Commissioner Marty Makary resigned in May 2026 after a rocky 13-month tenure amid leadership turmoil.\n6. [sq2 | question_description | MODERATE cred 90 | UP | DATED] FDA approved Omisirge, a modified allogeneic cord-blood cell therapy for hematologic malignancies, in April 2023, establishing precedent for cell-therapy approvals in this space.\n7. [sq2 | article_search | MODERATE cred 65 | DOWN | DATED] FDA denied or discouraged at least eight drug applications in the past year, including gene therapies, citing concerns about supporting evidence (March 2026).\n8. [sq2 | article_search | MODERATE cred 60 | DOWN | RECENT] FDA withheld approval of a melanoma drug despite clinical benefit, amid confusion under Makary\u0027s leadership (May 2026).\n9. [sq3 | question_description | MODERATE cred 85 | DOWN | DATED] The Orca-T review extension was driven by updated CMC information, indicating CMC was an active area of FDA focus.\n10. [sq3 | article_search | WEAK cred 50 | NEUTRAL | DATED] A massive eye drop recall in 2026 reflected ongoing FDA manufacturing-inspection issues, highlighting agency scrutiny of CMC/sterility (April 2026).\n\n## Cross-Market Signals\n\n### No signal found\n\nInformation gaps:\n - No Orca-T-specific news on inspection outcomes or CMC resolution status post-extension\n - Base rate for approval vs CRL when extension was CMC-only and no clinical data requested\n - No data on facility inspection status for Orca Bio manufacturing site\n - No expert/analyst commentary specifically on Orca-T\u0027s approval odds\n\nKey uncertainties:\n - Whether updated CMC package fully satisfies FDA reviewers\n - Impact of FDA leadership turnover and staffing on timely action\n - Whether FDA issues a second extension rather than acting by July 6, 2026\n - Whether facility inspection (if required) is completed and clean\n\n## Required pre-forecast walkthrough\n\nBefore giving probabilities, walk through these explicitly:\n (a) The time left until the question resolves.\n (b) The status quo outcome \u2014 what happens if nothing changes from today.\n (c) A brief scenario that results in NO.\n (d) A brief scenario that results in YES.\n\n## Calibration guidance\n\n- **Estimate each sub-question in isolation.** Do not let your answer to one sub-question anchor your answer to another. This is the core of Fermi decomposition \u2014 independence forces more careful reasoning per factor.\n- **Anchor on the status quo.** Require strong specific evidence to move far from it.\n- 0.05 / 0.95 require strong, multi-source evidence. Avoid \u003e0.97 or \u003c0.03 unless the outcome is already settled or near-tautological \u2014 overconfident misses are punished heavily by the log score.\n- **Anchor on prediction markets.** If liquid market prices (Polymarket / Kalshi) or a community forecast appear in the evidence, treat them as a strong, well-calibrated prior. Your final estimate should rarely sit more than ~15 percentage points from a liquid market on the SAME question \u2014 move further only with specific evidence the market lacks.\n- **Treat research as fallible, not ground truth.** A single-source or \"very recent\" claim \u2014 especially one the evidence flags as unverified, possibly AI-generated, or low-credibility \u2014 must not drive you to near-certainty. When a load-bearing fact is unverified, keep at least 10-15% on the chance it is wrong.\n- **Also provide a holistic estimate** \u2014 your overall gut feeling about the main question, BEFORE you see the mathematical combination. This serves as a sanity check: if the Fermi result and holistic estimate diverge wildly, something is wrong.\n\n## Output\n\nReturn ONLY valid JSON, no markdown fences:\n\n{\n \"rationale\": \"\u003caddress (a) (b) (c) (d) above \u2014 5-8 sentences total\u003e\",\n \"sub_question_estimates\": {\n \"sq1\": \u003cfloat in [0.01, 0.99]\u003e,\n \"sq2\": \u003cfloat in [0.01, 0.99]\u003e,\n \"sq3\": \u003cfloat in [0.01, 0.99]\u003e\n },\n \"holistic_p_yes\": \u003cfloat in [0.01, 0.99] \u2014 your overall estimate ignoring the decomposition\u003e,\n \"what_would_change_my_mind\": \"\u003c1-2 sentences: what new info would push you above 70% or below 30%\u003e\"\n}\n",
"holistic_p_yes": 0.44,
"models": [
"opus"
],
"p_yes": 0.5699000000000001,
"rationale": "(a) About 6 months remain until the Sept 1, 2026 cutoff, with the PDUFA target of July 6, 2026 falling comfortably inside that window. (b) Status quo: FDA already extended once for CMC reasons without requesting new clinical data, so the clinical package appears accepted and a decision by the PDUFA date is the baseline expectation. (c) NO scenario: a facility inspection finding or unresolved CMC/sterility deficiency triggers a CRL or a second extension, plausibly amplified by FDA leadership turnover and staffing \u0027chaos\u0027 reported in early-mid 2026. (d) YES scenario: the updated CMC package satisfies reviewers, any required inspection is clean, and FDA approves on or before July 6 given the strong cell-therapy precedent (Omisirge). The core uncertainty is whether the CMC fix is fully adequate; FDA has recently been notably tougher on applications, which tempers approval odds toward a coin-flip rather than a high-confidence yes.",
"sub_question_estimates": {
"sq1": 0.76,
"sq2": 0.6,
"sq3": 0.55
},
"what_would_change_my_mind": "A clean facility inspection report or company confirmation that FDA\u0027s CMC concerns are resolved would push me above 70%; news of a fresh inspection finding, a second extension, or a CRL-type signal would push me below 30%."
},
"plan": {
"combination_logic": "weighted_average",
"domain": "health",
"n_sub_qs": 3,
"n_tools": 3,
"reasoning_approach": "Each sub-question captures a contributing factor (timely action, approval-vs-CRL, and CMC risk) that blend into the probability of approval before the deadline; weighted_average combines them since they are correlated and all depend on the same underlying review trajectory.",
"sub_questions": [
{
"id": "sq1",
"question": "Will the FDA take action on the Orca-T BLA on or before its July 6, 2026 PDUFA target action date (rather than another extension/delay)?",
"rationale": "The PDUFA date falls before the Sept 1, 2026 resolution cutoff, so timely action is a precondition for a Yes resolution. A second extension would push action close to or beyond the deadline.",
"weight": 0.4
},
{
"id": "sq2",
"question": "Given timely FDA action, will the action be an approval rather than a CRL?",
"rationale": "The core driver: the extension was for CMC information with no new clinical data requested, suggesting the clinical package was satisfactory and odds favor approval.",
"weight": 0.45
},
{
"id": "sq3",
"question": "Are there CMC, manufacturing, or inspection issues that could trigger a CRL or further delay for Orca-T?",
"rationale": "CMC was the reason for the extension; unresolved manufacturing/facility inspection issues are a common cause of cell-therapy CRLs and would block approval.",
"weight": 0.15
}
],
"tool_requests": [
{
"parameters": {
"brief": "Find the latest status of Orca Bio\u0027s Orca-T BLA for hematologic malignancies: FDA PDUFA date July 6 2026, any approval, CRL, advisory committee, manufacturing/CMC updates, or further review extensions.",
"max_searches": 4,
"question_title": "Will FDA approve Orca-T for hematologic malignancies before September 1, 2026?"
},
"target_sub_questions": [
"sq1",
"sq2",
"sq3"
],
"tool_name": "claude_news"
},
{
"parameters": {
"lookback_days": 180,
"queries": [
"Orca-T FDA approval BLA hematologic malignancies",
"Orca Bio PDUFA July 2026 CRL",
"Orca-T CMC manufacturing FDA review extension"
]
},
"target_sub_questions": [
"sq1",
"sq2",
"sq3"
],
"tool_name": "article_search"
},
{
"parameters": {
"code": "import numpy as np\n# Base rate estimate: probability of first-cycle/timely FDA approval for a BLA after a CMC-only extension (no new clinical data requested)\n# Historical first-cycle approval rate for BLAs/NDAs ~ 60-70%; CMC-only extension with strong clinical package is favorable\np_timely_action = 0.85 # action by/near PDUFA, before Sept 1 deadline\np_approval_given_action = 0.70 # approval vs CRL given action\np_no_cmc_block = 0.78 # CMC/inspection resolved\nsims = np.random.default_rng(0)\nest = p_timely_action * p_approval_given_action * p_no_cmc_block\nprint(\u0027rough combined estimate\u0027, round(est,3))",
"description": "Rough base-rate triangulation for FDA approval given a CMC-only extension."
},
"target_sub_questions": [
"sq1",
"sq2",
"sq3"
],
"tool_name": "code_execution"
}
]
},
"question": {
"close_time": "2026-06-19T06:00:00Z",
"description": "## Description\nFDA [extended](https://orcabio.com/orca-bio-announces-fda-review-extension-of-bla-for-orca-t-for-the-treatment-of-hematologic-malignancies/) the BLA review for Orca-T and set a new PDUFA target action date of July 6, 2026; the extension followed updated CMC information and did not request additional clinical data. FDA [approved](https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell) Omisirge, a substantially modified allogeneic cord-blood-based cell therapy, for patients with hematologic malignancies on April 17, 2023.\n\n`{\"format\": \"bot_tournament_question\", \"info\": {\"hash_id\": \"b1535d606941245d\", \"sheet_id\": \"47\"}}`\n\n## Resolution Criteria\nThis question resolves as Yes if FDA approves Orca-T for any hematologic malignancy indication before September 1, 2026. It resolves as No if FDA issues a CRL, extends review without approval, the application is withdrawn, or no approval is public before September 1, 2026.",
"question_type": "binary",
"title": "Will FDA approve Orca-T for hematologic malignancies before September 1, 2026?"
},
"research": {
"cross_market_brief": "## Cross-Market Signals\n\n### No signal found",
"errors": [],
"has_cross_market": true,
"n_errors": 0,
"n_tools": 3,
"tools": [
{
"elapsed_s": 39.68,
"error": null,
"success": true,
"summary": "10 citations",
"tool_name": "claude_news"
},
{
"elapsed_s": 1.42,
"error": null,
"success": true,
"summary": "20 articles",
"tool_name": "article_search"
},
{
"elapsed_s": 0.0,
"error": null,
"success": true,
"summary": "Rough base-rate triangulation for FDA approval given a CMC-o",
"tool_name": "code_execution"
}
]
},
"synthesis": {
"evidence": [
{
"claim": "FDA extended Orca-T BLA review and set a new PDUFA target action date of July 6, 2026.",
"credibility": 92,
"direction": "UP",
"priced_in": true,
"recency": "DATED",
"source": "question_description",
"strength": "STRONG",
"sub_question_id": "sq1"
},
{
"claim": "The extension followed updated CMC information and FDA did not request additional clinical data.",
"credibility": 90,
"direction": "UP",
"priced_in": true,
"recency": "DATED",
"source": "question_description",
"strength": "STRONG",
"sub_question_id": "sq1"
},
{
"claim": "A rough base-rate triangulation for FDA approval given a CMC-only extension produced a combined estimate of 0.464.",
"credibility": 35,
"direction": "NEUTRAL",
"priced_in": false,
"recency": "VERY_RECENT",
"source": "code_execution",
"strength": "WEAK",
"sub_question_id": "sq1"
},
{
"claim": "FDA watchers warn of internal \u0027chaos,\u0027 staff losses, and regulatory delays affecting the agency\u0027s ability to keep up with approvals (March 2026).",
"credibility": 60,
"direction": "DOWN",
"priced_in": true,
"recency": "DATED",
"source": "article_search",
"strength": "MODERATE",
"sub_question_id": "sq1"
},
{
"claim": "FDA Commissioner Marty Makary resigned in May 2026 after a rocky 13-month tenure amid leadership turmoil.",
"credibility": 70,
"direction": "NEUTRAL",
"priced_in": true,
"recency": "RECENT",
"source": "article_search",
"strength": "MODERATE",
"sub_question_id": "sq1"
},
{
"claim": "FDA approved Omisirge, a modified allogeneic cord-blood cell therapy for hematologic malignancies, in April 2023, establishing precedent for cell-therapy approvals in this space.",
"credibility": 90,
"direction": "UP",
"priced_in": true,
"recency": "DATED",
"source": "question_description",
"strength": "MODERATE",
"sub_question_id": "sq2"
},
{
"claim": "FDA denied or discouraged at least eight drug applications in the past year, including gene therapies, citing concerns about supporting evidence (March 2026).",
"credibility": 65,
"direction": "DOWN",
"priced_in": true,
"recency": "DATED",
"source": "article_search",
"strength": "MODERATE",
"sub_question_id": "sq2"
},
{
"claim": "FDA withheld approval of a melanoma drug despite clinical benefit, amid confusion under Makary\u0027s leadership (May 2026).",
"credibility": 60,
"direction": "DOWN",
"priced_in": true,
"recency": "RECENT",
"source": "article_search",
"strength": "MODERATE",
"sub_question_id": "sq2"
},
{
"claim": "The Orca-T review extension was driven by updated CMC information, indicating CMC was an active area of FDA focus.",
"credibility": 85,
"direction": "DOWN",
"priced_in": true,
"recency": "DATED",
"source": "question_description",
"strength": "MODERATE",
"sub_question_id": "sq3"
},
{
"claim": "A massive eye drop recall in 2026 reflected ongoing FDA manufacturing-inspection issues, highlighting agency scrutiny of CMC/sterility (April 2026).",
"credibility": 50,
"direction": "NEUTRAL",
"priced_in": true,
"recency": "DATED",
"source": "article_search",
"strength": "WEAK",
"sub_question_id": "sq3"
}
],
"information_gaps": [
"No Orca-T-specific news on inspection outcomes or CMC resolution status post-extension",
"Base rate for approval vs CRL when extension was CMC-only and no clinical data requested",
"No data on facility inspection status for Orca Bio manufacturing site",
"No expert/analyst commentary specifically on Orca-T\u0027s approval odds"
],
"key_uncertainties": [
"Whether updated CMC package fully satisfies FDA reviewers",
"Impact of FDA leadership turnover and staffing on timely action",
"Whether FDA issues a second extension rather than acting by July 6, 2026",
"Whether facility inspection (if required) is completed and clean"
],
"n_evidence": 10
},
"timings": {
"forecast": 34.75,
"plan": 13.79,
"research": 39.68,
"synthesis": 18.9
}
}